

The Role of Ivabradine in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

Donaldo Emiliano Silva López¹, Francisco Javier Junez Villicaña², Ivana Leilani Junez Villicaña², Ashley Michelle García Luis³, Alondra Camyla Carreón Fuentes⁴, Juan Felipe Garibay Chávez⁵, Roberto Andrés Rodríguez Quiroz⁶, Héctor Roberto Rincón Figueroa⁴

¹Tecnológico de Monterrey campus Monterrey. Monterrey, Mexico.

²Universidad Michoacana de San Nicolas de Hidalgo. Mexico.

³Universidad Autonoma de Aguascalientes. Aguascalientes, Mexico.

⁴Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, Mexico.

⁵Universidad Autónoma de Zacatecas. Zacatecas, Mexico.

⁶Tecnológico de Monterrey campus Ciudad de México. Mexico.

ABSTRACT

Background: Heart failure with reduced ejection fraction (HFrEF) represents a complex clinical syndrome characterized by neurohormonal activation and autonomic dysregulation, wherein an elevated resting heart rate is a well-established independent prognosticator of adverse cardiovascular outcomes. This review delineates the pathophysiology of sinus node dysfunction in HFrEF and the specific electropharmacological profile of ivabradine, a novel agent that selectively inhibits the I_f* current in the sinoatrial node, thereby inducing pure heart rate reduction without negative inotropic or lusitropic effects. The discourse progresses from the foundational SHIFT trial, which demonstrated a significant reduction in the composite endpoint of cardiovascular death and hospitalization for worsening heart failure in patients with a sinus rhythm heart rate ≥ 70 beats per minute, to subsequent real-world evidence and sub-analyses that have refined its application. We synthesize the current evidence positioning ivabradine within the contemporary, rapidly evolving guideline-directed medical therapy (GDMT) paradigm for HFrEF, highlighting its role in patients who remain tachycardic despite maximally tolerated beta-blockade. The safety profile and specific patient phenotypes most likely to derive benefit are also examined, providing a holistic overview of its place in modern cardiovascular therapeutics.

KEYWORDS: Ivabradine, Heart Failure with Reduced Ejection Fraction, I_f* Channel Inhibitor, Sinus Rhythm, Tachycardia, Guideline-Directed Medical Therapy, Pharmacotherapy.

ARTICLE DETAILS

Published On:
25 September 2025

Available on:
<https://ijmscrs.com>

INTRODUCTION

The management of chronic heart failure with reduced ejection fraction has been revolutionized by pharmacotherapies that antagonize maladaptive neurohormonal pathways, including the renin-angiotensin-aldosterone system and the sympathetic nervous system. Despite the proven mortality benefit of beta-adrenergic blocking agents, a significant proportion of patients exhibit persistent sinus tachycardia, a marker of excessive sympathetic tone and impaired autonomic balance. This elevated heart rate is not merely an epiphenomenon but a

direct contributor to the worsening of cardiac function; it shortens diastole, compromising coronary perfusion and ventricular filling, while simultaneously increasing myocardial oxygen demand and promoting detrimental ventricular remodeling. 1,2

Therefore, the therapeutic targeting of heart rate represents a rational and physiologically sound strategy beyond neurohormonal blockade. Ivabradine emerged as a first-in-class agent offering a novel mechanism of action, specifically and selectively inhibiting the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels responsible for the

The Role of Ivabradine in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

I_f current, the primary pacemaker current governing the spontaneous diastolic depolarization phase of sinoatrial node cells. This unique mechanism confers a pure heart rate-lowering effect, distinct from the negative inotropic and vasodilatory properties of other rate-controlling medications. This manuscript endeavors to comprehensively explore the journey of ivabradine from its foundational physiological principles to its established role in current clinical practice. It will elaborate on the intricate pathophysiology linking heart rate to HFrEF progression, detail the pharmacodynamic and pharmacokinetic properties of the drug, and critically appraise the landmark clinical trials and meta-analyses that form the bedrock of its evidence base. 2,3

Pathophysiological

The pathophysiological rationale for heart rate reduction with ivabradine in heart failure with reduced ejection fraction is intricately linked to the deleterious sequelae of chronic tachycardia on the failing myocardium. In the compromised heart, an elevated resting heart rate initiates a vicious cycle of worsening cardiac function and further neurohormonal activation. Tachycardia directly abbreviates diastole, the critical period for coronary perfusion. As the majority of coronary blood flow occurs during diastole, its truncation severely impairs myocardial oxygen delivery, particularly to the subendocardial layers, exacerbating ischemia in a ventricle already operating on a precarious oxygen balance. 3,4

Concurrently, reduced diastolic duration impairs left ventricular filling, elevating filling pressures and contributing to the pulmonary and systemic congestion characteristic of heart failure decompensation. Furthermore, persistent tachycardia increases myocardial oxygen consumption, placing an unsustainable metabolic demand on the cardiomyocyte. At the cellular and molecular level, chronic tachycardia promotes maladaptive remodeling by activating stress-signaling pathways, inducing calcium mishandling within the sarcoplasmic reticulum, and promoting oxidative stress and inflammation, all of which accelerate cardiomyocyte apoptosis and foster progressive ventricular dilation and systolic dysfunction. This pathophysiological backdrop is compounded by the autonomic dysfunction inherent in HFrEF, where sympathetic nervous system overdrive and diminished parasympathetic tone lead to inappropriate sinus tachycardia. While beta-blockers address the neurohormonal axis, their negative inotropic and hypotensive effects often preclude uptitration to doses sufficient to achieve adequate heart rate control, leaving many patients with persistent tachycardia. Ivabradine intervenes precisely at this juncture by selectively inhibiting the I_f current, a key mixed sodium-potassium current conducted through hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the sinoatrial node. This current is fundamental to the pacemaker cell's spontaneous phase 4 diastolic depolarization. By attenuating the slope of this depolarization, ivabradine reduces heart rate in a dose-

dependent manner without affecting myocardial contractility, vascular tone, or intracardiac conduction. 3,4

This pure heart rate reduction breaks the aforementioned cycle by prolonging diastole, thereby improving coronary perfusion and ventricular filling, reducing myocardial oxygen demand, and ultimately attenuating the processes driving maladaptive remodeling. The evidence confirms that this physiological benefit translates into clinical improvement, reducing the incidence of heart failure hospitalizations in patients with symptomatic HFrEF and sinus rhythm who remain tachycardic despite evidence-based beta-blocker therapy. 5

Indications And Contraindications

The precise therapeutic targeting of ivabradine in heart failure with reduced ejection fraction necessitates a rigorous understanding of its specific indications and absolute contraindications, which are directly derived from its unique mechanism of action and the pivotal clinical trial eligibility criteria that demonstrated its efficacy. The paramount indication for ivabradine is as an adjunctive therapy in adult patients with chronic HFrEF who, despite receiving stable background guideline-directed medical therapy inclusive of a maximally tolerated evidence-based dose of a beta-blocker (or in those with a genuine intolerance or contraindication to beta-blockade), remain in sinus rhythm with a persistently elevated resting heart rate of 77 beats per minute or greater while symptomatic. This specific heart rate threshold is not arbitrary but is firmly rooted in the entry criteria and subsequent subgroup analyses of the major outcome trial, which established that the clinical benefit on cardiovascular outcomes is most pronounced in this tachycardic cohort. The agent is further indicated to reduce the incidence of hospitalization for worsening heart failure in this specific patient population. 5,6

Conversely, the contraindications to ivabradine are critically important and are primarily dictated by its electrophysiological profile. Its use is absolutely contraindicated in patients presenting with acute decompensated heart failure requiring intravenous inotropic support due to the potential for hemodynamic compromise in such a tenuous state. It is prohibited in patients with severe hepatic impairment due to altered metabolism and the risk of drug accumulation. A cardinal contraindication is the presence of sinus node dysfunction, sinoatrial block, or any form of intrinsic sinoatrial disease, including a resting heart rate naturally below 60 beats per minute prior to initiation, as pharmacologically further lowering the heart rate in such individuals could precipitate profound bradycardia and symptomatic chronotropic incompetence. Similarly, it is contraindicated in patients with third-degree atrioventricular block unless a functioning permanent pacemaker is present to ensure adequate ventricular rate. Due to its mechanism of blocking the HCN channels, which are also expressed in the retina, it is not recommended in patients with pre-existing severe retinitis pigmentosa. 5,6

The Role of Ivabradine in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

Furthermore, its use is not advised in patients with atrial fibrillation or other arrhythmias that override sinus node function, as the drug would be ineffective in controlling the ventricular rate in such scenarios. Concomitant use with potent cytochrome P450 3A4 inhibitors, which can significantly elevate ivabradine plasma concentrations and the risk of serious bradycardia, is also contraindicated. Therefore, the application of ivabradine requires careful patient selection, focusing on those with appropriate sinus rhythm-mediated tachycardia while meticulously excluding those with predisposing conditions for severe bradycardia or significant drug interactions.⁶

Clinical evidence for ivabradine in HFrEF

The cornerstone of the clinical evidence supporting the use of ivabradine in chronic heart failure with reduced ejection fraction is the seminal SHIFT trial (Systolic Heart failure treatment with the I^f*inhibitor ivabradine Trial), a large-scale, multinational, randomized, double-blind, placebo-controlled study conducted in patients with symptomatic HFrEF, sinus rhythm, and a heart rate of 70 beats per minute or higher who were on background guideline-directed medical therapy, including maximally tolerated doses of beta-blockers. This landmark investigation demonstrated that the addition of ivabradine to standard care produced a highly significant reduction in the primary composite endpoint of cardiovascular death or hospitalization for worsening heart failure.⁶

This benefit was driven predominantly by a substantial reduction in heart failure hospitalizations, a key driver of morbidity, mortality, and healthcare costs in this population. Importantly, the trial established that the efficacy of ivabradine was directly contingent upon the magnitude of heart rate reduction achieved, with greater benefits observed in patients with higher baseline heart rates and those who achieved a larger absolute reduction, thereby solidifying the causal role of heart rate as a modifiable risk factor. Subsequent in-depth analyses of the SHIFT data provided further granularity, showing that ivabradine improved patient-reported outcomes, including New York Heart Association functional class and quality of life measures, and attenuated the progressive left ventricular remodeling process, as evidenced by reductions in left ventricular end-systolic and end-diastolic volumes and an increase in left ventricular ejection fraction over time.^{7,8}

Following the publication of SHIFT, a wealth of real-world evidence from large-scale registry studies and prospective observational cohorts across various healthcare systems has consistently corroborated the trial's findings, demonstrating that the use of ivabradine in routine clinical practice is associated with lower rates of heart failure readmission and improved survival, mirroring the efficacy seen in the controlled trial environment. Furthermore, post-hoc analyses have explored its effects in specific subphenotypes, such as patients with diabetes mellitus or those with very high heart rates, generally confirming consistent benefit. In the

contemporary era, the role of ivabradine has been further refined amidst the introduction of new foundational therapies for HFrEF, namely angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). While no large randomized trial has specifically tested ivabradine on top of this modern quadruple therapy, its mechanism of action remains uniquely complementary.^{9,10}

Current international guidelines from major cardiology societies have integrated this evidence, endorsing ivabradine as a therapeutic consideration to reduce heart failure hospitalization in symptomatic patients with HFrEF who remain in sinus rhythm with a heart rate persistently at or above 70 beats per minute despite treatment with a beta-blocker at maximum tolerated evidence-based dose or who have a contraindication to beta-blocker use. Thus, the clinical evidence base, from a robust pivotal trial through extensive real-world validation, firmly supports ivabradine as a targeted heart rate-lowering strategy that confers significant morbidity benefits within the comprehensive, multifaceted pharmacological management of chronic HFrEF.^{11,12,13}

Conclusion

In conclusion, the journey of ivabradine from a novel electrophysiological agent to an established therapeutic option in heart failure with reduced ejection fraction is a compelling narrative of translational medicine, elegantly connecting cellular physiology to tangible clinical outcomes. The foundational pathophysiology of HFrEF, characterized by neurohormonal excess and autonomic imbalance, establishes persistent sinus tachycardia not merely as a biomarker of disease severity but as a direct contributor to a vicious cycle of worsening ischemia, impaired diastolic filling, increased myocardial oxygen demand, and accelerated maladaptive remodeling. Ivabradine addresses this specific pathophysiological niche through its highly selective inhibition of the sinoatrial node's I^f*current, a mechanism that affords pure heart rate reduction devoid of negative inotropic or hemodynamic effects that can limit other neurohormonal antagonists.

The robust evidence from the SHIFT trial and its multitude of sub-analyses provides a powerful validation of this approach, demonstrating that targeted heart rate lowering in appropriately selected patients yields significant reductions in the risk of heart failure hospitalization, improves left ventricular systolic function and reverse remodeling, and enhances patient-centered quality of life metrics. The subsequent accumulation of extensive real-world evidence has consistently reinforced these benefits, affirming its efficacy and safety in diverse clinical practice settings beyond the rigor of a controlled trial. Within the contemporary therapeutic paradigm for HFrEF, which now includes angiotensin receptor-neprilysin inhibitors and SGLT2 inhibitors, ivabradine continues to hold a distinct and valuable role. It serves as a specialized adjunctive therapy for the specific phenotype of patients who remain symptomatic with sinus tachycardia despite maximally tolerated guideline-

The Role of Ivabradine in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

directed medical therapy. Therefore, ivabradine exemplifies the principle of precision medicine in heart failure management, offering a targeted intervention based on a deep understanding of underlying physiology, supported by a solid evidence base, and ultimately contributing to the overarching goal of reducing morbidity and improving the clinical trajectory for patients living with this chronic and debilitating syndrome.

REFERENCES

- I. Komajda M, Isnard R, Cohen-Solal A: Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. *Eur J Heart Fail.* 2017, 19:1495-1503. 10.1002/ejhf.876
- II. Pal N, Sivaswamy N, Mahmood M, et al.: Response to letter regarding article, "the effect of selective heart rate slowing in heart failure with preserved ejection fraction". *Circulation.* 2016, 132:1719-1725. 10.1161/CIRCULATIONAHA.115.017119
- III. Borlaug BA, Kass DA: Ventricular-vascular interaction in heart failure. *Heart Fail Clin.* 2008, 4:23-36. 10.1016/j.ccl.2011.06.004
- IV. Zdrengea D, Beudean M, Pop D, Zdrengea V: Four hundred meters walking test in the evaluation of heart failure patients. *Rom J Intern Med.* 2010, 48:33-38.
- V. Hassanein A, Desai A, Verma A, et al.: EXCEED: exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. *Ther Adv Cardiovasc Dis.* 2009, 3:429-439. 10.1177/1753944709341301
- VI. Ponikowski P, Voors AA, Anker SD, et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail.* 2016, 37:2129-2200. 10.1002/ejhf.592
- VII. Gladden JD, Linke WA, Redfield MM: Heart failure with preserved ejection fraction. *Pflugers Arch.* 2014, 466:1037-1053. 10.1007/s00424-014-1480-8
- VIII. Swedberg K, Komajda M, Bohm M, et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet.* 2010, 376:875-885. 10.1016/S0140-6736(10)61198-1
- IX. Steinberg BA, Zhao X, Heidenreich PA, et al.: Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. *Circulation.* 2012, 126:65-75. 10.1161/CIRCULATIONAHA.111.080770
- X. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH: Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. *J Am Coll Cardiol.* 2013, 62:1330-1338. 10.1016/j.jacc.2013.06.043
- XI. Yamamoto K: β -blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. *J Cardiol.* 2015, 66:189-194. 10.1016/j.jjcc.2015.02.004
- XII. Edelmann F, Musial-Bright L, Gelbrich G, et al.: Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: insights from the CIBIS-ELD trial. *JACC Heart Fail.* 2016, 4:140-149. 10.1016/j.jchf.2015.10.008
- XIII. Conraads VM, Metra M, Kamp O, et al.: Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. *Eur J Heart Fail.* 2012, 14:219-225. 10.1093/eurjhf/hfr161